The Company continues to anticipate collaboration revenue to be between $60 million and $70 million. Management has updated its total research and development expenses to be between $210 million and $220 million and reiterated total general and administrative expenses to be between $60 million and $70 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
- Alector to Host Mid-Year Earnings Conference Call
- Alector participates in a conference call with Cantor Fitzgerald
- Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer’s Association International Conference® 2024 (AAIC®)
- Alector presents baseline characteristics for INVOKE-2 Phase 2 trial of AL002